Votrient Related Published Studies
Well-designed clinical trials related to Votrient (Pazopanib)
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. [2011.06]
Pazopanib in renal cell carcinoma. [2010.12.15]
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. [2010.12]
Pazopanib: in advanced renal cell carcinoma. [2010.10.01]
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. [2010.08.01]
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. [2010.02.20]
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. [2010.01.20]
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. [2010]
Pazopanib in renal cell carcinoma. [2010]
Pazopanib: in advanced renal cell carcinoma. [2010]
Well-designed clinical trials possibly related to Votrient (Pazopanib)
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. [2011.06]
Major clinical research advances in gynecologic cancer 2009. [2009.12]
Other research related to Votrient (Pazopanib)
Reversible posterior leukoencephalopathy syndrome induced by pazopanib. [2012]
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced
anaplastic thyroid cancer. [2012]
Prognostic or predictive plasma cytokines and angiogenic factors for patients
treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis
of phase 2 and phase 3 trials. [2012]
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer:
a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer
Clinical Trials Consortium study. [2012]
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing
administered as crushed tablet or oral suspension in patients with advanced solid
tumors. [2012]
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. [2011.10.18]
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. [2011.10.01]
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. [2011.09]
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. [2011.08.03]
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. [2011.07]
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. [2011.06.20]
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. [2011.06.18]
Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors. [2011.04]
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. [2011.03.11]
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. [2011.03.05]
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. [2011.01.01]
Nursing considerations with pazopanib therapy: focus on metastatic renal cell
carcinoma. [2011]
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. [2010.11]
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. [2010.10.05]
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. [2010.10]
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. [2010.10]
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. [2010.09.17]
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). [2010.08]
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. [2010.07.01]
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. [2010.07.01]
Effect of pazopanib on tumor microenvironment and liposome delivery. [2010.06]
Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. [2010.06]
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. [2010.04.27]
Pazopanib: Clinical development of a potent anti-angiogenic drug. [2010.04.22]
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. [2010.04]
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. [2010.04]
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. [2010.03.15]
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. [2010]
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with
a high-fat or low-fat meal in patients with advanced solid tumors. [2010]
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with
pazopanib plus lapatinib combination therapy in patients with advanced and
recurrent cervical cancer. [2010]
Pazopanib: therapeutic developments. [2009.12]
Pazopanib: an antiangiogenic drug in perspective. [2009.11]
Pazopanib for the treatment of renal cell carcinoma and other malignancies. [2009.09]
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). [2009.07.01]
Phase I trial of pazopanib in patients with advanced cancer. [2009.06.15]
Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. [2009.04]
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. [2008.12]
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. [2008.08.14]
Other possibly related research studies
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. [2010.09]
[Treatment with oral agents for breast cancer] [2010.07]
Novel Targeted therapy for advanced renal carcinoma: trials in progress. [2010.09]
Systemic therapy for metastatic renal cell carcinoma in treatment naive patients: a risk-based approach. [2010.10]
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. [2010.07]
[Antiangionic drugs in soft tissue sarcoma] [2010.06]
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. [2010]
New therapeutic strategies for renal cell carcinoma. [2010.01]
Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. [2010.06]
Recent advances and future directions in the management of metastatic renal cell carcinoma. [2010.03]
[Management of metastatic HER2-positive breast cancer: present and future] [2010.03]
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. [2010.08]
Molecular basis for the treatment of renal cell carcinoma. [2010.01]
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? [2010.03]
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. [2010.01]
Gateways to clinical trials. [2009.10]
Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. [2009.12]
Angiogenesis inhibitors in the management of breast cancer. [2010.02]
Tyrosine kinase inhibitors and the thyroid. [2009.12]
Anti-angiogenesis agents in metastatic or recurrent cervical cancer. [2010.02]
Gateways to clinical trials. [2009.07]
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. [2009.08]
New treatment approaches in renal cell carcinoma. [2009.11]
Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. [2009.09.08]
Emerging pharmacologic therapies for wet age-related macular degeneration. [2009]
[Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab] [2009.05]
Systemic therapy of advanced urothelial cancer. [2009.08]
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. [2009.05.15]
VEGF inhibitors for the treatment of neovascular age-related macular degeneration. [2009.05]
Targeted therapies in metastatic renal cancer in 2009. [2009.05]
Tumoral angiogenesis and breast cancer. [2009.03]
Targeted therapy in the treatment of metastatic renal cell cancer. [2009]
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. [2008.12]
Signaling inhibitors in metastatic renal cell carcinoma. [2008.09]
[Systemic therapy of metastasizing renal cell carcinoma] [2008.10]
Novel drugs for renal cell carcinoma. [2008.10]
Current and emerging targeted therapies for metastatic breast cancer. [2011.10.17]
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. [2011.11]
Second-line therapy for refractory renal-cell carcinoma. [2011.09.21]
Indirect treatment comparison of bevacizumab + interferon-alpha-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. [2011]
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. [2011.10.01]
Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. [2011.09]
Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. [2011.06]
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. [2011.03]
[Treatment of metastatic renal cell carcinoma]. [2011.04]
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. [2011.05]
|
